Alexion Pharmaceuticals Inc (Pre-Merger) ALXN-MX:

*Data is delayed
Last | EST
()
52 week range
-
Loading...
  • Open-
  • Day High-
  • Day Low-
  • Prev Close-
  • 52 Week High-
  • 52 Week High Date-
  • 52 Week Low-
  • 52 Week Low Date-

Key Stats

  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change20.14

KEY STATS

  • Open-
  • Day High-
  • Day Low-
  • Prev Close-
  • 52 Week High-
  • 52 Week High Date-
  • 52 Week Low-
  • 52 Week Low Date-
  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change20.14

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Alexion Pharmaceuticals Inc (Pre-Merger)

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s marketed products include SOLIRIS (eculizumab), Strensiq (asfotase alfa), Kanuma (sebelipase alfa), ULTOMIRIS, Andexxa and Ondexxya. The Company’s clinical development programs include ALXN1210, ALXN1810, ALXN1720, ALXN1830, ALXN1840 and ABY-039. The Company’s ULTOMIRIS is a long-acting C5 inhibitor discovered and...
Address
121 Seaport Blvd
Boston, MA
02210-2050
United States